{"title":"Topical Painkillers Drugs and Patches","description":"\u003cp\u003eAnti-inflammatories and painkillers to be applied to the skin instead of ingested: skin gels and foams based on diclofenac, ketoprofen and ibuprofen, prolonged-release medicated plasters, revulsive ointments. They act on the painful point for contractures, strains, sprains, back pain and joint pain. Fast shipping in 24\/48 hours.\u003c\/p\u003e","products":[{"product_id":"dicloreum-antinfiammatorio-locale-10-cerotti-medicati-180-mg","title":"Dicloreum Local Anti-inflammatory 10 Medicated Patches 180 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to diclofenac, acetylsalicylic acid or other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients of the finished product, as well as to isopropanol. • Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal inflammatory drugs (NSAIDs). • Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. • Third trimester of pregnancy and breastfeeding (see section 4.6). • Patients with active peptic ulcer. \u003ci\u003eChildren and adolescents:\u003c\/i\u003e Use in children and adolescents under 16 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf diclofenac medicated plasters are used on large skin surfaces and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac). The medicated plaster must be applied only to intact and healthy skin and must not be applied to damaged skin or open wounds. The patches should not come into contact with the eyes or mucous membranes. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. - Do not use with an occlusive dressing that does not allow air to pass through. - Treatment must be stopped immediately if a skin rash develops after application of the medicated plaster. - Do not simultaneously administer topically or systemically another medicinal product based on diclofenac or other NSAIDs. - Although systemic effects should be limited, the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or bleeding diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more predisposed to side effects. - Patients should be advised not to expose themselves to direct sunlight or light from sunlamps for approximately one day after removal of the medicated plaster in order to reduce the risk of photosensitivity. Local anti-inflammatory Dicloreum contains: - methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (even delayed). - 420 mg of propylene glycol per patch which may cause skin irritation. - a perfume containing allergens (amyl cinnamale, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate) which may cause reactions allergic.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, the most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); Not known: cannot be estimated from available data.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Rash with pustules\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis (e.g. bullous erythema), dry skin\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Reactions at the administration site\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the risk\/benefit ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":40207822913651,"sku":"042685014","price":24.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-dicloreum-antinfiammatorio-locale-10-cerotti-medicati-180-mg-farmacia-dottor-tili-1254211180.jpg?v=1793011245"},{"product_id":"voltaren-emulgel-gel-2-100-gr","title":"Voltaren Emulgel Gel 2% 100 Gr","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • History of asthma, angioedema, urticaria or acute rhinitis following the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • During the third trimester of pregnancy. • Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e cannot be excluded if the preparation is used on large skin areas and for a prolonged period\u003ci\u003e.\u003c\/i\u003e \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e it must only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e it can be used with non-occlusive dressings, but must not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g which may cause skin irritation. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains butylated hydroxytoluene which may cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains pungent eucalyptus scent, an aroma which in turn contains benzyl alcohol, citronellol, coumarin, d-limonene, eugenol, geraniol, linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects include mild, transient skin reactions at the application site. In very rare cases, allergic reactions may occur. Undesirable effects (Table 1) are listed below by organ, system\/system and MedDRA frequency. Frequencies are defined as: very common (≥ 1\/10) common (≥ 1\/100 to \u003c1\/10); uncommon (≥ 1\/1,000 to \u003c 1\/100); rare (≥ 1\/10,000 to \u003c 1\/1,000); very rare (\u003c 1\/10,000) not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Rash with pustules.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioedema.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Dermatitis (including contact dermatitis), rash, erythema, eczema, pruritus.\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reaction, allergic reactions.\u003c\/p\u003e\n\u003cp\u003eNot known | Burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":46369425260871,"sku":"034548154","price":18.51,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/novartis-farma-spa-voltaren-emulgel-gel-2-100-gr-farmacia-dottor-tili-1213792507.jpg?v=1767112290"},{"product_id":"transact-lat-10-cerotti-antidolorifici-flurbiprofene-40-mg","title":"Transact Lat 10 Pain Relief Patches Flurbiprofen 40 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTRANSACT Lat is indicated for the local symptomatic treatment of painful conditions affecting the musculoskeletal system.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, or to any of the excipients listed in paragraph 6.1. Hypersensitivity to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). History of gastrointestinal bleeding or perforation related to previous NSAID treatment. Active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer, or gastrointestinal hemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Severe heart failure. Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicated plaster must only be applied to intact skin, not to open wounds or lesions and must not be applied during a bath or shower. The medicated plaster must not come into contact with the eyes or be applied to mucous membranes or eyes. The medicated plaster must not be used with occlusive dressings. Application of the medicated plaster should be discontinued if a skin rash develops. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). \u003cb\u003e \u003ci\u003e \u003cu\u003eGastrointestinal effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal events. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. The concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events (see below and section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking Flurbiprofen, treatment should be discontinued. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Adequate monitoring and appropriate instructions are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure since, in association with treatment with NSAIDs, fluid retention and edema have been found. The product is contraindicated in patients with severe heart failure (see section 4.3). Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. \u003cb\u003e \u003ci\u003e \u003cu\u003eSkin reactions\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003e \u003ci\u003e \u003cu\u003eRespiratory reactions\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. \u003cb\u003e \u003ci\u003e \u003cu\u003eHepatic impairment\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Caution is required in patients with hepatic impairment. There is a greater risk of gastro-intestinal bleeding and fluid retention. NSAIDs should be avoided in severe liver disease. \u003cb\u003e \u003ci\u003e \u003cu\u003eRenal impairment\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e NSAIDs should be avoided if possible or used with caution in patients with renal impairment; The lowest possible dosage should be used for the shortest time and renal function should be monitored. NSAIDs can cause kidney failure, especially in patients with pre-existing kidney problems. \u003cb\u003e \u003ci\u003e \u003cu\u003eOther Reactions\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Caution should be used when initiating treatment with NSAIDs such as flurbiprofen in patients with considerable dehydration. Particular caution must be taken when treating patients with severely reduced renal, cardiac or hepatic function as the use of NSAIDs can lead to deterioration of renal function. In such patients the dosage should be kept as low as possible and renal function should be monitored. Prolonged or repeated use of products for skin use can give rise to sensitization phenomena. In the presence of hypersensitivity reactions it is necessary to interrupt therapy. To avoid any phenomena of hypersensitivity or photosensitization, avoid exposure to direct sunlight, including the solarium, during treatment and in the following two weeks. \u003cb\u003e \u003ci\u003e \u003cu\u003eReduction in female fertility\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Long-term use of some NSAIDs is associated with reduced female fertility which is reversible by stopping treatment. \u003cb\u003e \u003ci\u003e \u003cu\u003eSLE and mixed connective tissue disease\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Aseptic meningitis has rarely been reported with NSAIDs. Patients with connective tissue diseases, such as systemic lupus erythematosus, may be particularly susceptible (see section 4.8). \u003cb\u003e \u003ci\u003e \u003cu\u003eElderly people\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. \u003cb\u003eDiuretics, ACE inhibitors and angiotensin II antagonists\u003c\/b\u003e: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclooxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Flurbiprofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and on a periodic basis thereafter. \u003cb\u003eCardiac glycosides\u003c\/b\u003e: NSAIDs can exacerbate heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides. \u003cb\u003eAnticoagulants, such as warfarin\u003c\/b\u003e: increased anticoagulant effect. \u003cb\u003eAspirin\u003c\/b\u003e: As with other NSAID-containing medicines, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects. \u003cb\u003eAnti-aggregating agents\u003c\/b\u003e: increased risk of gastrointestinal bleeding. \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/b\u003e: increased risk of gastrointestinal bleeding. \u003cb\u003eLithium salts\u003c\/b\u003e: decrease in lithium elimination. \u003cb\u003eMethotrexate\u003c\/b\u003e: Caution is advised in case of concomitant administration of flurbiprofen and methotrexate as NSAIDs may increase methotrexate levels. \u003cb\u003eCyclosporine\u003c\/b\u003e: increased risk of nephrotoxicity with NSAIDs. \u003cb\u003eCorticosteroids\u003c\/b\u003e: increased risk of gastrointestinal ulcer or bleeding with NSAIDs. \u003cb\u003eCox-2 inhibitors and other NSAIDs\u003c\/b\u003e: Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects. \u003cb\u003eQuinolone antibiotics\u003c\/b\u003e: Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. \u003cb\u003eMifepristone\u003c\/b\u003e: NSAIDs should not be taken for 8-12 days after administration of mifepristone as NSAIDs may reduce the effects of mifepristone. \u003cb\u003eTacrolimus\u003c\/b\u003e: possible increased risk of nephrotoxicity in case of co-administration with NSAIDs. \u003cb\u003eZidovudine\u003c\/b\u003e: increased risk of blood toxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and haematoma in haemophilia patients affected by HIV in simultaneous treatment with Zidovudine and other NSAIDs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse events that have been associated with Flurbiprofen are reported below, listed by systemic organ classification frequency. Frequencies are defined as: very common (≥1\/10), common, (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000) and not known (impossible to estimate from the available data). Within each frequency group, adverse events are reported in order of decreasing severity.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eClassification by systems and organs \u003c\/b\u003e | \u003cb\u003eFrequency \u003c\/b\u003e | \u003cb\u003eSide effects \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system. | Not known: | thrombocytopenia, aplastic anemia, agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eneutropenia, hemolytic anemia.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders. | Not known: | anaphylactic reaction, angioedema, hypersensitivity.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders. | Not known: | depression.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders. | Not known: | dizziness cerebrovascular accidents, optic neuritis, migraine, paraesthesia, tingling, dysesthesia, confusion, hallucination, dizziness, drowsiness, aseptic meningitis (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eEye pathologies. | Not known: | vision impairment.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders. | Not known: | tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac diseases. | Not known: | edema, heart failure.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies. | Not known: | hypertension, arterial thromboembolic events.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal diseases. | Not known: | respiratory tract reactivity (asthma, bronchospasm and dyspnea).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders. | Very rare: | pancreatitis.\u003c\/p\u003e\n\u003cp\u003eNot known: | abdominal pain, dyspepsia, nausea, vomiting, diarrhoea, melena, haematemesis, ulcerative stomatitis, peptic ulcer, perforated ulcer, haemorrhagic ulcer, gastritis, gastrointestinal haemorrhage, flatulence, constipation, exacerbation of colitis, Crohn's disease.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue. | Very rare: | bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).\u003c\/p\u003e\n\u003cp\u003eNot known: | rash, itching, urticaria, erythema, purpura, eruptions.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders. | Not known: | nephrotoxicity (including interstitial nephritis, nephrotic syndrome), renal failure.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site. | Not known: | malaise, fatigue.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazionireazioni-avverse.\u003c\/p\u003e","brand":"Recordati","offers":[{"title":"Default Title","offer_id":46488677974343,"sku":"028741015","price":24.61,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/recordati-spa-transact-lat-10-cerotti-antidolorifici-flurbiprofene-40-mg-farmacia-dottor-tili-1213792492.webp?v=1767112477"},{"product_id":"flector-180mg-5-cerotti-medicati","title":"Flector 180mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of: • Joints; • Muscles; • Tendons; • Ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to acetylsalicylic acid or to other analgesics or other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. • Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns, or wounds. • Third trimester of pregnancy (see section 4.6). • Patients with active peptic ulcer. \u003ci\u003e \u003cu\u003eChildren and adolescents\u003c\/u\u003e \u003c\/i\u003e: Use in children and adolescents under 16 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf diclofenac medicated plasters are used on large skin surfaces and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac). The medicated plaster must be applied only to intact and healthy skin and must not be applied to damaged skin or open wounds. The patches should not come into contact with the eyes or mucous membranes. Asthmatic patients with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The use, especially if prolonged, of this as well as other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Although systemic absorption is minimal, the use of FLECTOR, as with any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant. The administration of FLECTOR should be suspended in women who have fertility problems or who are undergoing fertility investigations. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. • Do not use with an occlusive dressing that does not allow air to pass through. • Treatment should be stopped immediately if a skin rash develops after applying the medicated plaster. • Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. • Although systemic effects should be low, the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or bleeding diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more predisposed to side effects. • Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removal of the medicated plaster to reduce the risk of photosensitivity. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e. FLECTOR contains: - methyl parahydroxybenzoate, propyl parahydroxybenzoate: may cause allergic reactions (even delayed); - 420 mg of propylene glycol in each patch: may cause skin irritation; - an aroma (perfume) in turn containing amyl cinnamal, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate: may cause reactions allergic\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible. Clinical investigations carried out with FLECTOR medicated plaster used in conjunction with other steroidal and non-steroidal anti-inflammatory drugs (salazopyrin, hydroxyquinoline, etc.) have not highlighted any interaction phenomena. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended (see section 4.8).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1 \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Rash with pustules\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Reactions at the administration site\u003c\/p\u003e\n\u003cp\u003eFollowing applications for long periods of time on large skin surfaces, due to the amount of active ingredient that is absorbed, the appearance of systemic undesirable effects, especially at the gastrointestinal level, cannot be excluded. The use of the product in association with other drugs containing diclofenac can give rise to phenomena of hypersensitivity to light, skin rash with the formation of vesicles, eczema, erythema and, in rare cases, severe skin reactions (severe Stevens-Johnson, Lyell syndrome) (see section 4.5). \u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":51131188150599,"sku":"027757032","price":16.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-flector-180mg-5-cerotti-medicati-farmacia-dottor-tili-1213792401.jpg?v=1767132569"},{"product_id":"flector-180mg-10-cerotti-medicati","title":"Flector 180mg 10 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of: • Joints; • Muscles; • Tendons; • Ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to acetylsalicylic acid or to other analgesics or other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. • Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns, or wounds. • Third trimester of pregnancy (see section 4.6). • Patients with active peptic ulcer. \u003ci\u003e \u003cu\u003eChildren and adolescents\u003c\/u\u003e \u003c\/i\u003e: Use in children and adolescents under 16 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf diclofenac medicated plasters are used on large skin surfaces and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac). The medicated plaster must be applied only to intact and healthy skin and must not be applied to damaged skin or open wounds. The patches should not come into contact with the eyes or mucous membranes. Asthmatic patients with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The use, especially if prolonged, of this as well as other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Although systemic absorption is minimal, the use of FLECTOR, as with any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant. The administration of FLECTOR should be suspended in women who have fertility problems or who are undergoing fertility investigations. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. • Do not use with an occlusive dressing that does not allow air to pass through. • Treatment should be stopped immediately if a skin rash develops after applying the medicated plaster. • Do not simultaneously administer topically or systemically another medicine containing diclofenac or other NSAIDs. • Although systemic effects should be low, the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or bleeding diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more predisposed to side effects. • Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removal of the medicated plaster to reduce the risk of photosensitivity. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e. FLECTOR contains: - methyl parahydroxybenzoate, propyl parahydroxybenzoate: may cause allergic reactions (even delayed); - 420 mg of propylene glycol in each patch: may cause skin irritation; - an aroma (perfume) in turn containing amyl cinnamal, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate: may cause reactions allergic\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible. Clinical investigations carried out with FLECTOR medicated plaster used in conjunction with other steroidal and non-steroidal anti-inflammatory drugs (salazopyrin, hydroxyquinoline, etc.) have not highlighted any interaction phenomena. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended (see section 4.8).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1 \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Rash with pustules\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Reactions at the administration site\u003c\/p\u003e\n\u003cp\u003eFollowing applications for long periods of time on large skin surfaces, due to the amount of active ingredient that is absorbed, the appearance of systemic undesirable effects, especially at the gastrointestinal level, cannot be excluded. The use of the product in association with other drugs containing diclofenac can give rise to phenomena of hypersensitivity to light, skin rash with the formation of vesicles, eczema, erythema and, in rare cases, severe skin reactions (severe Stevens-Johnson, Lyell syndrome) (see section 4.5). \u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":51131235336519,"sku":"027757044","price":23.16,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-flector-180mg-10-cerotti-medicati-farmacia-dottor-tili-1213792316.jpg?v=1767143369"},{"product_id":"voltaren-emulgel-gel-2-180-gr","title":"Voltaren Emulgel Gel 2% 180 Gr","description":"\u003cp\u003eVoltaren Emulgel Gel \u003cstrong\u003epainkiller and anti-inflammatory\u003c\/strong\u003e for \u003cstrong\u003emuscle and joint pain\u003c\/strong\u003e based on Diclofenac (2%). Voltaren Emulgel is a local treatment of \u003cstrong\u003epainful and inflammatory states\u003c\/strong\u003e: of a rheumatic or traumatic nature of the joints, such as \u003cstrong\u003eosteoarthritis and arthritis\u003c\/strong\u003e; of the muscles, in case of \u003cstrong\u003econtractures or injuries\u003c\/strong\u003e; of tendons and ligaments, in the presence of \u003cstrong\u003etendinitis\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Voltaren Emulgel Gel 2% 180 Gr used? What is it for?\u003c\/h3\u003e\u003cp dir=\"\"\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp dir=\"\"\u003e100 g of Voltaren Emulgel contain 2.32 g of diclofenac diethylammonium, equivalent to 2 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g of gel), butylated hydroxytoluene (0.2 mg\/g of gel), pungent eucalyptus perfume. For the full list of excipients, see section 6.1.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp dir=\"\"\u003eButylated hydroxytoluene, carbomers, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, oleic alcohol, propylene glycol, pungent eucalyptus perfume, purified water.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow is Voltaren Emulgel Gel 2% 180 Gr taken?\u003c\/h3\u003e\u003cp dir=\"\"\u003eFor cutaneous use. Adults over 18 years of age, Voltaren Emulgel 2% gel provides pain relief for up to 12 hours: apply Voltaren Emulgel 2% gel 2 times a day on the area to be treated (preferably in the morning and evening), rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2-4 g of Voltaren Emulgel 2% gel (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of ​​400-800 cm^2. After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. Warning: use only for short treatment periods. The duration of treatment depends on the indication for use and the clinical response. The gel should not be used for more than 14 days without medical advice. Consult your doctor if symptoms persist or worsen after 7 days of treatment. Adolescents aged 14 to 18: apply Voltaren Emulgel 2% gel 2 times a day on the area to be treated (preferably in the morning and evening), rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2-4 g of Voltaren Emulgel 2% gel (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of ​​400-800 cm^2. After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult a doctor. Children under 14 years: Insufficient data are available on the efficacy and safety of children and adolescents under 14 years (see section 4.3 Contraindications). Therefore, the use of Voltaren Emulgel 2% gel is contraindicated in children under 14 years of age. Elderly (over 65 years): the usual dosage for adults can be used.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Voltaren Emulgel Gel 2% 180 Gr not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp dir=\"\"\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1; history of asthma, angioedema, urticaria or acute rhinitis following the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs); during the third trimester of pregnancy; use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp dir=\"\"\u003eSide effects include mild, transient skin reactions at the application site. In very rare cases, allergic reactions may occur. Side effects are listed below by organ, system\/system and MedDRA frequency. Frequencies are defined as: very common (\u003e= 1\/10) common (\u003e= 1\/100 to \u003c1\/10); uncommon (\u003e= 1\/1,000 to \u003c 1\/100); rare (\u003e= 1\/10,000 to \u003c 1\/1,000); very rare (\u003c 1\/10,000) not known (frequency cannot be estimated from the available data). Infections and infestations. Very rare: rash with pustules. Immune system disorders. Very rare: hypersensitivity (including urticaria), angioedema. Respiratory, thoracic and mediastinal disorders. Very rare: asthma. Pathologies of the skin and subcutaneous tissue. Common: dermatitis (including contact dermatitis), rash, erythema, eczema, pruritus; rare: bullous dermatitis; very rare: photosensitivity reaction, allergic reactions; not known: burning sensation at the application site, dry skin. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp dir=\"\"\u003eSince the systemic absorption of diclofenac following topical application is very low, interactions are very unlikely.\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Voltaren Emulgel Gel 2% 180 Gr be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp dir=\"\"\u003ePregnancy: the systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: the inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increases from less than 1%, up to approximately 1.5%. The risk is believed to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality; furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors had been administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Diclofenac is contraindicated during the third trimester of pregnancy. Breastfeeding: Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of Voltaren Emulgel 2% no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, Voltaren Emulgel 2% must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4 Special warnings and precautions for use).\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp dir=\"\"\u003eThe possibility of systemic adverse events with the application of Voltaren Emulgel 2% cannot be excluded if the preparation is used on large skin areas and for a prolonged period. Voltaren Emulgel 2% must be applied only to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. Voltaren Emulgel 2% can be used with non-occlusive dressings, but must not be used with an occlusive dressing that does not allow air to pass through. Important information about some excipients: Voltaren Emulgel 2% gel contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g which may cause skin irritation. Voltaren Emulgel 2% gel contains butylated hydroxytoluene which may cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. Voltaren Emulgel 2% gel contains pungent eucalyptus scent, an aroma which in turn contains benzyl alcohol, citronellol, coumarin, d-limonene, eugenol, geraniol, linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Voltaren Emulgel Gel 2% 180 Gr stored?\u003c\/h3\u003e\u003cp dir=\"\"\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp\u003e180 gr\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":51131285078343,"sku":"034548230","price":27.08,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/novartis-farma-spa-voltaren-emulgel-gel-2-180-gr-farmacia-dottor-tili-1213792236.jpg?v=1767133870"},{"product_id":"reparil-2-5-gel-40g","title":"Reparil 2% + 5% gel 40g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMinor traumatology\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients. REPARIL should not be used on open lesions (wounds), mucous membranes and skin areas treated with radiation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere is no risk of addiction and dependence. Since it is a preparation for topical applications, its use must be exclusively external. The use, especially prolonged, of products for topical use can give rise to sensitization phenomena. This medicine contains lavender oil and bitter orange blossom oil with d-limonene, farfalle and linalool as fragrances. These substances can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interactions with other medicinal products have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn rare cases, hypersensitivity reactions such as redness, scaling and dehydration of the skin may appear. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Viatris Healthcare","offers":[{"title":"Default Title","offer_id":51131314929991,"sku":"036397026","price":11.58,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/viatris-healthcare-limited-reparil-2-5-gel-40g-farmacia-dottor-tili-1213792116.jpg?v=1767135988"},{"product_id":"lasonil-antidolore-10-gel-50g","title":"Lasonil painkiller 10% gel 50g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of bruises, sprains, myalgia, muscle strains, stiff neck.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients. Due to the possibility of cross-sensitization, the medicine must not be administered to patients in whom acetylsalicylic acid or other non-steroidal anti-inflammatory drugs have caused asthma, rhinitis, urticaria or other allergic manifestations. - Pregnancy. - Breastfeeding - Children and adolescents under 14 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is advisable to avoid applying LASONIL ANTIDOLORE to open wounds or skin lesions. The use of LASONIL ANTIDOLORE, like any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. The administration of LASONIL ANTIDOLORE must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use of LASONIL ANTIDOLORE, especially if prolonged, can give rise to local sensitization phenomena: at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, interrupt treatment and adopt adequate therapeutic measures. To avoid more serious hypersensitivity or photosensitization phenomena, the patient must not expose himself to direct sunlight, including the solarium, during treatment and in the following two weeks (see section 4.8). Do not use LASONIL ANTIDOLORE together with another NSAID or, in any case, do not use more than one NSAID at a time. Severe skin reactions Severe skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of the reaction occurs in most cases within the first month of treatment. Acute generalized exanthematous pustulosis (PEAG) has been reported in connection with ibuprofen-containing medicinal products. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003eImportant information about some excipients of LASONIL ANTIDOLORE\u003c\/b\u003e: the medicine contains sodium methyl para-oxybenzoate and sodium ethyl para-oxybenzoate which may cause allergic reactions (possibly delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe paucity of data and the uncertainties relating to their application to the clinical situation do not allow definitive conclusions to be drawn on possible interactions with other drugs for the continuous use of ibuprofen; no clinically relevant interactions have been found with the occasional use of ibuprofen. Bear in mind, in any case, that Ibuprofen can increase the effects of anticoagulants such as warfarin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Skin reactions with erythema, itching, irritation, sensation of heat or burning and contact dermatitis have been reported with some non-steroidal anti-inflammatory drugs derived from propionic acid for local or transdermal use. Some cases of bullous eruptions of varying severity, including Stevens Johnson syndrome, and toxic epidermal necrolysis (very rarely) have also been reported. Frequency not known: - Acute generalized exanthematous pustulosis (PEAG) (see section 4.4) - Photosensitivity reactions (see section 4.4) \u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131316797767,"sku":"042154017","price":9.81,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-lasonil-antidolore-10-gel-50g-farmacia-dottor-tili-1213792110.jpg?v=1767136111"},{"product_id":"momendol-10-gel-50g","title":"Momendol 10% gel 50g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMomendol 10% gel is indicated in adults and children over 12 years of age for the local treatment of pain in muscular and joint diseases such as myalgia, lumbago, stiff neck, bursitis, tendinitis, tenosynovitis, periarthritis, muscle strains, contusions, hematomas. Adjuvant of orthopedic and rehabilitation therapies.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid using the gel on eyes, mucous membranes, wounds and\/or skin lesions. The amount of active ingredient absorbed through the skin does not reach blood concentrations such as to expose one to the risk of side effects or such as to make the warnings relating to systemic administration of the drug applicable. However, we do not recommend the use of Momendol 10% gel to patients in whom acetylsalicylic acid and\/or other NSAIDs induce allergic reactions and we also do not recommend its use in patients with active allergic reactions or a positive history. To prevent any phenomena of hypersensitivity or photosensitization, avoid exposure to direct sunlight, including the solarium, during treatment and in the following two weeks. Stop treatment if skin rashes or irritation occur. This medicine contains a fragrance with D-Limonene. D-Limonene can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies have been carried out d\u003cb\u003e’\u003c\/b\u003e interaction. The product is poorly absorbed at a systemic level therefore interactions with other drugs are unlikely, although they cannot be excluded.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects organized according to the MedDRA System Organ classification. The frequency is defined as follows: very common (≥1\/10), common (≥1\/100 to \u003c1\/10), uncommon (≥1\/1000 to \u003c1\/100), rare (≥1\/10,000 to \u003c1\/1000), very rare (\u003c1\/10,000), not known (cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eSystem organ class according to MedDRA\/Frequency\u003c\/i\u003e \u003c\/b\u003e | \u003cb\u003eSIDE EFFECT\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue \u003c\/b\u003e \u003csup\u003e(1)\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eNot known\u003c\/i\u003e | Erythema, Pruritus, Skin irritation, Burning sensation of the skin, Contact dermatitis, Bullous rash, Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eNot known\u003c\/i\u003e | Raising awareness \u003csup\u003e(2)\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eNot known\u003c\/i\u003e | Warm sensation\u003c\/p\u003e\n\u003cp\u003e\u003csup\u003e1)\u003c\/sup\u003e Adverse skin reactions have been reported with some non-steroidal anti-inflammatory drugs for cutaneous or transdermal use, derivatives of propionic acid. \u003csup\u003e2)\u003c\/sup\u003e The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case, suspend treatment and adopt suitable therapeutic measures. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Angelini Pharma","offers":[{"title":"Default Title","offer_id":51131323023687,"sku":"025829197","price":11.44,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-momendol-10-gel-50g-farmacia-dottor-tili-1213792096.jpg?v=1767136332"},{"product_id":"lasonil-antidolore-10-gel-120gr","title":"Lasonil painkiller 10% gel 120gr","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of bruises, sprains, myalgia, muscle strains, stiff neck.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients. Due to the possibility of cross-sensitization, the medicine must not be administered to patients in whom acetylsalicylic acid or other non-steroidal anti-inflammatory drugs have caused asthma, rhinitis, urticaria or other allergic manifestations. - Pregnancy. - Breastfeeding - Children and adolescents under 14 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is advisable to avoid applying LASONIL ANTIDOLORE to open wounds or skin lesions. The use of LASONIL ANTIDOLORE, like any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. The administration of LASONIL ANTIDOLORE must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use of LASONIL ANTIDOLORE, especially if prolonged, can give rise to local sensitization phenomena: at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, interrupt treatment and adopt adequate therapeutic measures. To avoid more serious hypersensitivity or photosensitization phenomena, the patient must not expose himself to direct sunlight, including the solarium, during treatment and in the following two weeks (see section 4.8). Do not use LASONIL ANTIDOLORE together with another NSAID or, in any case, do not use more than one NSAID at a time. Severe skin reactions Severe skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of the reaction occurs in most cases within the first month of treatment. Acute generalized exanthematous pustulosis (PEAG) has been reported in connection with ibuprofen-containing medicinal products. Ibuprofen should be discontinued at the first appearance of signs and symptoms of severe skin reactions, such as rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003eImportant information about some excipients of LASONIL ANTIDOLORE\u003c\/b\u003e: the medicine contains sodium methyl para-oxybenzoate and sodium ethyl para-oxybenzoate which may cause allergic reactions (possibly delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe paucity of data and the uncertainties relating to their application to the clinical situation do not allow definitive conclusions to be drawn on possible interactions with other drugs for the continuous use of ibuprofen; no clinically relevant interactions have been found with the occasional use of ibuprofen. Bear in mind, in any case, that Ibuprofen can increase the effects of anticoagulants such as warfarin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Skin reactions with erythema, itching, irritation, sensation of heat or burning and contact dermatitis have been reported with some non-steroidal anti-inflammatory drugs derived from propionic acid for local or transdermal use. Some cases of bullous eruptions of varying severity, including Stevens Johnson syndrome, and toxic epidermal necrolysis (very rarely) have also been reported. Frequency not known: - Acute generalized exanthematous pustulosis (PEAG) (see section 4.4) - Photosensitivity reactions (see section 4.4) \u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131332526407,"sku":"042154029","price":13.76,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-lasonil-antidolore-10-gel-120gr-farmacia-dottor-tili-1213792064.jpg?v=1767137147"},{"product_id":"dicloreum-antinfiammatorio-locale-3-schiuma-cutanea-50g","title":"Dicloreum local anti-inflammatory 3% skin foam 50g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e§ Hypersensitivity to diclofenac, to any of the excipients, to acetylsalicylic acid and other non-steroidal anti-inflammatory drugs, as well as to isopropanol. § Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs) and isopropanol. § Third trimester of pregnancy (see section 4.6 \u003ci\u003eFertility, pregnancy and breastfeeding\u003c\/i\u003e). § Children and adolescents under 14 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac). Topical Diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. In elderly patients and\/or with gastric problems, the concomitant use of systemic anti-inflammatory drugs is not recommended. LOCAL ANTI-INFLAMMATORY DICLOREUM should be used with caution in patients who have had a hypersensitivity reaction to NSAIDs or analgesics in the past, e.g. asthma attacks, skin rashes or acute allergic rhinitis. Asthmatic patients, with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to antirheumatic treatment carried out with NSAIDs more often than other patients. The use, especially if prolonged, of other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Discontinue treatment if skin rash develops after application of the product. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. DICLOREUM LOCAL ANTI-INFLAMMATORY contains potassium sorbate which can cause local skin reactions (e.g. contact dermatitis). This medicine contains 7.5 mg of benzyl alcohol per dose. Benzyl alcohol can cause allergic reactions. Benzyl alcohol may cause mild local irritation. This medicine contains a mint\/eucalyptus fragrance which in turn contains geraniol, limonene and linalool which may cause allergic reactions. To reduce any photosensitization phenomena, it is advisable not to expose yourself excessively to the sun during use. \u003cb\u003eKeep the medicine out of the sight and reach of children.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely. However, in high-dose and prolonged treatments, keep in mind the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); Not known: cannot be estimated from available data.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Rash with pustules\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eThe use of the medicine in combination with other drugs containing diclofenac can give rise to phenomena of hypersensitivity to light, skin rash with the formation of vesicles, eczema, erythema and severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51131339505991,"sku":"042685040","price":17.11,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-dicloreum-antinfiammatorio-locale-3-schiuma-cutanea-50g-farmacia-dottor-tili-1213792022.jpg?v=1767148869"},{"product_id":"voltadol-140mg-5-cerotti-medicati","title":"Voltadol 140mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, to acetylsalicylic acid or to other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. Patients with a history of asthma, angioedema, urticaria or acute rhinitis after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. Third trimester of pregnancy (see section 4.6). Patients with active peptic ulcer. Children and adolescents under the age of 16.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf VOLTADOL is used for a prolonged period of time, the possibility of systemic adverse events cannot be excluded. VOLTADOL should only be applied to intact, healthy skin, and should not be applied to damaged skin or open wounds. The patches must not come into contact with the eyes or mucous membranes and must not be swallowed. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Treatment should be stopped immediately if a skin rash develops after application of the medicated plaster. Patients with asthma, chronic obstructive bronchial diseases, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The administration of VOLTADOL must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and establish a suitable therapy. Although systemic absorption is minimal, the use of VOLTADOL is not recommended in women planning to become pregnant. Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. The use of VOLTADOL in combination with other drugs containing diclofenac can give rise to severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). Given the route of administration, the risk of systemic effects is lower, however the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis. NSAIDs should be used with particular caution in elderly patients who are more predisposed to side effects. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. Patients should be advised not to expose themselves to direct sunlight or light from sunlamps for approximately one day after removal of the medicated plaster in order to reduce the risk of photosensitivity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac following the use of medicated plasters is low. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare: | Rash with pustules\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare: | Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare: | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality: | Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus\u003c\/p\u003e\n\u003cp\u003eRare: | Bullous dermatitis (e.g. bullous erythema), burning sensation at the application site, dry skin\u003c\/p\u003e\n\u003cp\u003eVery rare: | Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality: | Reactions at the administration site\u003c\/p\u003e\n\u003cp\u003eReporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51131353891143,"sku":"035520016","price":16.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadol-140mg-5-cerotti-medicati-farmacia-dottor-tili-1213791958.jpg?v=1767141090"},{"product_id":"dolaut-40-mg-g-25-g-gel-con-erogatore","title":"Dolaut 40 mg\/g 25 g gel with dispenser","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Children and adolescents: use in children and adolescents under 14 years of age is contraindicated. Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac). Therefore, particularly in patients with previous gastrointestinal diseases, the appearance of systemic side effects such as nausea, dyspepsia, heartburn, excitation, taste alteration, conjunctivitis cannot be excluded for DOLAUT. Topical Diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. DOLAUT contains propylene glycol which may cause mild localized skin irritation in some people. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. External use. KEEP OUT OF THE REACH OF CHILDREN.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, the most frequent first, using the following convention: very common (≥ 1\/10); common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); Not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Rush with pustules\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eNot known | Burning sensation at the application site, dry skin\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Neopharmed Gentili","offers":[{"title":"Default Title","offer_id":51730203115847,"sku":"033913017","price":16.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/neopharmed-gentili-spa-dolaut-40-mg-g-25-g-gel-con-erogatore-farmacia-dottor-tili-1213791433.jpg?v=1767138450"},{"product_id":"cerotto-bertelli-96-5-mg-368-6-mg-1-cerotto-16-24-cm-medicato","title":"Bertelli patch 96.5 mg (368.6 mg) 1 medicated patch 16×24 cm","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of muscle pain such as low back pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active ingredient or to other sources of capsaicinoids (for example pepper or chilli plants. Broken skin, wounds and eczema.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is advisable to remove Cerotto Bertelli using a cotton ball soaked in warm water or olive oil. The medicine should not be applied near the eyes or on the mucous membranes. During treatment, the application of additional heat sources (e.g. solar or infrared radiation, heat cushion or hot water) should be avoided. The effect of heat can also be intensified by physical activity (sweating). Treatment must be stopped if the heat effect occurs excessively. In this case the patch must be removed. If symptoms worsen while using the medicine, consult your doctor or pharmacist.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions of any kind with other medicinal products. No interaction studies have been performed. The patch is not intended to be applied at the same time as other topical products [e.g. other rubefacients (which increase perfusion and cause redness of the skin) or pain-relieving gels] at the same application site. Interactions with other products applied to the same application site may occur up to 12 hours after removal of the patch.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of the product for topical use, especially if prolonged, may give rise to sensitization phenomena. The active ingredient causes an increase in local blood circulation with marked redness of the skin and a sensation of heat. This reaction is part of the normal pharmacological action of the preparation and generally subsides shortly after removal of the patch. In rare cases (≈1\/10,000, \u003c1\/1,000): Skin hypersensitivity and allergic reactions (e.g. urticaria, vesicles and vesiculation at the application site) may occur. In these cases treatment must be stopped immediately. Especially during the first days of treatment, a sensation of irritation or itching may occur. If, in individual cases, the side effects experienced are excessive, treatment must be discontinued. \u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the Website: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Kelemata","offers":[{"title":"Default Title","offer_id":51730205901127,"sku":"004844027","price":9.41,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/kelemata-srl-cerotto-bertelli-96-5-mg-368-6-mg-1-cerotto-16x24-cm-medicato-farmacia-dottor-tili-1213791367.jpg?v=1767139768"},{"product_id":"voltadol-unidie-140-mg-5-cerotti-medicati","title":"Voltadol Unidie 140 mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term local treatment (maximum 7 days) of pain associated with muscle strains, sprains or bruises of arms and legs due to blunt trauma in adolescents from 16 years of age and in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Hypersensitivity to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs [NSAIDs] - Patients who have had attacks of asthma, urticaria or acute rhinitis in the past after the use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Patients with active peptic ulcer. - Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. - Third trimester of pregnancy. - Children and adolescents under 16 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicated plaster must not come into contact with or be applied to the eyes or mucous membranes. Undesirable effects can be reduced by using the lowest effective dose for the shortest possible time (see section 4.2). Bronchospasm may occur in patients who suffer or have suffered in the past from bronchial asthma or allergies. If a rash develops after applying the medicated plaster, treatment should be stopped immediately. After removal of the medicated plaster, patients should be informed of the need to avoid exposure to sunlight or sunlamps, in order to reduce the risk of photosensitization. It is not possible to exclude the possibility of systemic adverse events resulting from the application of diclofenac medicated plaster, if the product is used on large skin surfaces for a prolonged period of time. Although systemic effects may be minimal, the medicated plaster should be used with caution in patients with impaired renal, cardiac or hepatic function, or with a history of peptic ulcer, intestinal inflammation or haemorrhagic diathesis. Non-steroidal anti-inflammatory drugs should be used with caution in elderly patients, as these subjects are more exposed to the onset of side effects. Do not simultaneously administer, topically or systemically, any other medicinal product containing diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs). Butylated hydroxyanisole (E 320) may cause localized skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac with the methods of use of medicated plasters indicated on the label is very low, the risk of developing clinically significant interactions between drugs is negligible.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects are reported based on the following frequency categories:\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eVery common\u003c\/i\u003e \u003c\/b\u003e | \u003ci\u003e≥1\/10\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eMunicipality\u003c\/i\u003e \u003c\/b\u003e | \u003ci\u003eFrom ≥ 1\/100 to \u003c1\/10\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eUncommon\u003c\/i\u003e \u003c\/b\u003e | \u003ci\u003eFrom ≥1\/1,000 to \u003c1\/100\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eRare\u003c\/i\u003e \u003c\/b\u003e | \u003ci\u003eFrom ≥1\/10,000 to \u003c1\/1,000\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eVery rare\u003c\/i\u003e \u003c\/b\u003e | \u003ci\u003e\u0026lt;1\/10.000 \u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eNot known\u003c\/i\u003e \u003c\/b\u003e | \u003ci\u003eThe frequency cannot be estimated from the available data.\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and manifestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Pustular rash\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis (e.g. bullous erythema), dry skin\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Reactions at the administration site\u003c\/p\u003e\n\u003cp\u003eThe levels of diclofenac measured in systemic plasma according to the methods of use of the medicated plasters indicated on the label are very low when compared with those detected after oral intake of diclofenac. The risk of developing systemic side effects (such as gastric, hepatic and renal disorders, systemic hypersensitivity reactions), therefore, appears low with the use of the patch. However, if diclofenac is used on large skin surfaces and for long periods of time, the appearance of systemic side effects is possible. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730205999431,"sku":"048717021","price":18.51,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadol-unidie-140-mg-5-cerotti-medicati-farmacia-dottor-tili-1213791364.jpg?v=1767139832"},{"product_id":"voltalgan-3-50-g-schiuma-cutanea","title":"Voltalgan 3% 50 g skin foam","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Patients verified with a history of asthma, angioedema, urticaria or acute rhinitis after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds (see section 4.4). Third trimester of pregnancy (see section 4.6). Children and adolescents under the age of 14.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of VOLTALGAN cannot be excluded if the preparation is used on large skin areas and for a prolonged period. VOLTALGAN must be applied only to intact, unaffected skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. It is necessary to discontinue treatment if skin rash develops after application of the product. VOLTALGAN can be used with non-occlusive bandages, but must not be used with an occlusive dressing that does not allow air to pass through. In elderly patients and\/or with gastric problems, the concomitant use of systemic anti-inflammatory drugs is not recommended. Asthmatic patients, with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp), react, with asthmatic attacks, local inflammation of the skin, mucosa (Quincke's edema) or urticaria, to antirheumatic treatment carried out with NSAIDs, more often than other patients. The administration of VOLTALGAN must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use of VOLTALGAN, especially if prolonged, can give rise to local sensitization phenomena, which require the interruption of treatment and the adoption of adequate therapeutic measures. To reduce any photosensitivity phenomena, patients should be advised not to expose themselves to direct sunlight or light from sunlamps during use. In case of allergic reactions or more serious adverse reactions, it is necessary to suspend treatment with VOLTALGAN and establish adequate therapy. The use of the medicine in combination with other medicines containing diclofenac can give rise to severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). VOLTALGAN contains 7.5 mg of benzyl alcohol per dose (equivalent to 1.5 grams by weight). Benzyl alcohol may cause allergic reactions and mild local irritation. VOLTALGAN contains an aroma which in turn contains limonene. Limonene can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac following topical application is very low. In high-dose and prolonged treatments, keep in mind the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, the most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10), uncommon (≥ 1\/1000, \u003c 1\/100), rare (≥ 1\/10,000, \u003c 1\/1,000), very rare (\u003c1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare: | Hypersensitivity (including urticaria), angioneurotic edema\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare: | Rash with pustules\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare: | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality: | Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus\u003c\/p\u003e\n\u003cp\u003eRare: | Bullous dermatitis\u003c\/p\u003e\n\u003cp\u003eVery rare: | Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eNot known: | Dry skin, burning sensation upon application\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions \u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730206163271,"sku":"037645013","price":17.01,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltalgan-3-50-g-schiuma-cutanea-farmacia-dottor-tili-1213791360.jpg?v=1767139870"},{"product_id":"voltadol-140-mg-10-cerotti-medicati","title":"Voltadol 140 mg 10 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, to acetylsalicylic acid or to other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. Patients with a history of asthma, angioedema, urticaria or acute rhinitis after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. Third trimester of pregnancy (see section 4.6). Patients with active peptic ulcer. Children and adolescents under the age of 16.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf VOLTADOL is used for a prolonged period of time, the possibility of systemic adverse events cannot be excluded. VOLTADOL should only be applied to intact, healthy skin, and should not be applied to damaged skin or open wounds. The patches must not come into contact with the eyes or mucous membranes and must not be swallowed. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Treatment should be stopped immediately if a skin rash develops after application of the medicated plaster. Patients with asthma, chronic obstructive bronchial diseases, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The administration of VOLTADOL must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and establish a suitable therapy. Although systemic absorption is minimal, the use of VOLTADOL is not recommended in women planning to become pregnant. Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. The use of VOLTADOL in combination with other drugs containing diclofenac can give rise to severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). Given the route of administration, the risk of systemic effects is lower, however the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis. NSAIDs should be used with particular caution in elderly patients who are more predisposed to side effects. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. Patients should be advised not to expose themselves to direct sunlight or light from sunlamps for approximately one day after removal of the medicated plaster in order to reduce the risk of photosensitivity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac following the use of medicated plasters is low. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare: | Rash with pustules\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare: | Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare: | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality: | Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus\u003c\/p\u003e\n\u003cp\u003eRare: | Bullous dermatitis (e.g. bullous erythema), burning sensation at the application site, dry skin\u003c\/p\u003e\n\u003cp\u003eVery rare: | Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality: | Reactions at the administration site\u003c\/p\u003e\n\u003cp\u003eReporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730206589255,"sku":"035520028","price":24.09,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadol-140-mg-10-cerotti-medicati-farmacia-dottor-tili-1213791022.jpg?v=1767140125"},{"product_id":"miotens-0-25-30-ml-schiuma-cutanea","title":"Miotens 0.25% 30 ml skin foam","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLumbosciatica (back pain), cervico-brachial neuralgia (pain and contracture affecting the neck, shoulder and upper limbs), stubborn stiff necks, post-traumatic and post-operative pain syndromes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Flaccid paralysis, muscular hypotonicity. Pregnancy and breastfeeding (see 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe dosage should be appropriately reduced in the event of the appearance of side effects. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. If they occur, treatment must be discontinued and appropriate therapy instituted. MIOTENS CONTRACTURES AND PAIN contains propylene glycol: may cause skin irritation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo notes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of rash and skin erythema have been reported. See also paragraph 4.4.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":51730207015239,"sku":"042045017","price":12.56,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/dompe-farmaceutici-spa-miotens-0-25-30-ml-schiuma-cutanea-farmacia-dottor-tili-1213791065.jpg?v=1767140110"},{"product_id":"voltaren-emulgel-1-120-g-gel","title":"Voltaren Emulgel 1% 120 g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Patients in whom asthma, angioedema, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Third trimester of pregnancy. \u003cu\u003eChildren and adolescents\u003c\/u\u003e: Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac\u003ci\u003e).\u003c\/i\u003e Topical diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g and 4 mg of benzyl benzoate per dose (4 g) equivalent to 1 mg\/g which may cause skin irritation. \u003cb\u003e \u003ci\u003eVoltaren Emulgel 1% gel contains Cream 45 perfume, an aroma which in turn contains benzyl alcohol, citral, citronellol, coumarin, d-limonene, eugenol, farinasol, geraniol, linalool which may cause allergic reactions.\u003c\/i\u003e \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: very common (≥1\/10), common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Rash with pustules.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reaction, allergic reactions.\u003c\/p\u003e\n\u003cp\u003eNot known | Burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":51730207375687,"sku":"034548204","price":15.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/novartis-farma-spa-voltaren-emulgel-1-120-g-gel-farmacia-dottor-tili-1213791095.jpg?v=1767140310"},{"product_id":"dicloreum-unidie-136-mg-5-cerotti-medicati","title":"Dicloreum Unidie 136 mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDICLOREUM UNIDIE is indicated for the local treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance (ibuprofen) or to any of the excipients. The use of DICLOREUM UNIDIE is contraindicated in subjects in whom a previous hypersensitivity to acetylsalicylic acid or other analgesics or non-steroidal anti-inflammatory drugs has occurred, in patients with previous episodes of bronchospasm, angioedema or anaphylactoid reactions. The administration of DICLOREUM UNIDIE should be avoided in patients suffering from active peptic ulcers, bronchial asthma or suffering from severe renal and hepatic insufficiency. The use of DICLOREUM UNIDIE should also be avoided in patients with a history of gastrointestinal haemorrhage or perforation relating to previous active treatments or a history of recurrent haemorrhage\/peptic ulcer (two or more distinct episodes of demonstrated ulceration or bleeding), on therapy with anticoagulants (see section 4.5) and finally in cases of severe heart failure. Also avoid applying the medicated plaster on damaged skin or in areas with dermatoses or infections. Avoid contact with eyes and mucous membranes. The use of DICLOREUM UNIDIE is contraindicated during the third trimester of pregnancy and breastfeeding (see section 4.6) and in children under 12 years.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe plasma levels of ibuprofen achieved after administration of the medicated plaster are much lower than those obtained through systemic administration and therefore the onset of systemic side effects is likely to be much reduced compared to systemic use. However, if medicated plasters are used for a prolonged period of time it is not possible to exclude the possibility of systemic adverse events. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Analgesics, antipyretics and non-steroidal anti-inflammatory drugs (non-selective NSAIDs and selective COX-2 inhibitors), including ibuprofen, can cause potentially serious hypersensitivity reactions in subjects not previously exposed to this type of drugs. These reactions include asthma attacks, skin rashes, allergic rhinitis and anaphylactic-type reactions. Like other NSAIDs, ibuprofen can mask signs of infection. Elderly: Caution should be used when treating elderly patients who are generally more predisposed to adverse events. Asthmatic patients, with obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react more often than other patients to treatment with NSAIDs, with asthma attacks, local inflammation of the skin and mucosa (Quincke's edema) or urticaria. Gastrointestinal haemorrhage, ulceration and perforation, which may be fatal, have been reported during treatment with all NSAIDs at any time, with or without warning symptoms or previous history of serious gastrointestinal events. Use caution when administering DICLOREUM UNIDIE in patients with a history of peptic ulcer or gastrointestinal bleeding not secondary to the administration of NSAIDs and in cases of ulcerative colitis and Crohn's disease. Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal haemorrhage) particularly in the initial stages of treatment. Caution should be exercised in patients taking concomitant medications that may increase the risk of ulceration or haemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as aspirin (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking DICLOREUM UNIDIE, treatment should be discontinued. It is also not recommended in cases of haemorrhagic diathesis, severe liver or kidney dysfunction and in cases of heart failure. Caution should be exercised in patients with a history of hypertension and\/or mild to moderate congestive heart failure since fluid retention and edema have been reported in association with treatment with NSAIDs. NSAIDs can reduce the effect of diuretics and other antihypertensive drugs (see section 4.5). Ibuprofen may cause water and sodium, potassium retention in patients who have never suffered from kidney disease due to its effects on renal perfusion. This may cause edema or heart failure or hypertension in predisposed patients. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other renal pathological changes. Ibuprofen, like other NSAIDs, can inhibit platelet aggregation and has shown evidence of prolonging bleeding time in healthy subjects. Therefore, patients with coagulation defects or on anticoagulant therapy should be carefully observed. On rare occasions, aseptic meningitis has been observed in patients receiving ibuprofen. Prolonged or repeated use of products for skin use can give rise to local phenomena awareness. Analgesics, antipyretics, non-steroidal anti-inflammatory drugs can cause potentially serious hypersensitivity reactions (anaphylactoid reactions), even in subjects not previously exposed to this type of drugs. The risk of hypersensitivity reactions after taking ibuprofen is greater in subjects who have experienced such reactions after the use of other analgesics, antipyretics, non-steroidal anti-inflammatory drugs and in subjects with bronchial hyperreactivity (asthma), hay fever, nasal polyposis or chronic obstructive respiratory diseases or previous episodes of angioedema. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Severe hypersensitivity reactions (e.g. anaphylactic shock) have been observed rarely. In the presence of significant adverse reactions (skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis) and hypersensitivity reactions it is necessary to immediately discontinue therapy and consult the doctor for the purpose of instituting suitable therapy. After a short therapy without appreciable results, consult your doctor. There is no experience on the use of DICLOREUM UNIDIE in children and therefore its use is not recommended in subjects under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of ibuprofen patches is unlikely to have interactions with other medicines. However, the possibility of competition between absorbed ibuprofen and other drugs with high binding to plasma proteins cannot be excluded. Do not use the product together with other drugs for oral or local use containing ibuprofen or other NSAIDs.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by reducing the duration of treatment to the shortest possible time needed to control symptoms. Data from clinical studies of the product were used to determine the frequency of adverse reactions. The following convention was adopted for frequency classification: Very common ≥1\/10; Common ≥1\/100 - \u003c1\/10; Uncommon ≥1\/1,000 - \u003c1\/100; Rare ≥1\/10,000 - \u003c1\/1,000; Very rare \u003c1\/10,000, not known (cannot be estimated from the available data). \u003cb\u003eTable 1: \u003c\/b\u003eIncidence of treatment-associated side effects in controlled clinical trials.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystem organ classification and frequency \u003c\/b\u003e | \u003cb\u003eUnwanted reaction \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eNervous system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipalities | Dry mouth, headache, dysgeusia\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipalities | Nausea\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipalities | Facial edema, vesicles\u003c\/p\u003e\n\u003cp\u003eNot known | Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the musculoskeletal system and connective tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipalities | General malaise\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery Common | Mild erythema\u003c\/p\u003e\n\u003cp\u003eMunicipalities | Itching, burning, clear erythematous manifestation, skin exfoliation and cracking\u003c\/p\u003e\n\u003cp\u003eAll adverse events encountered in clinical trials were mild and transient in nature. Side effects reported from literature data\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystem organ classification and frequency \u003c\/b\u003e | \u003cb\u003eUnwanted reaction \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system pathologies\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eNot known | Local hypersensitivity\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eNot known | Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eNot known | Contact dermatitis\u003c\/p\u003e\n\u003cp\u003eNot known | Numbness and tingling at the application site\u003c\/p\u003e\n\u003cp\u003eCases of extensive and serious dermatological lesions such as erythema multiforme, Quincke's edema and, very rarely, bullous reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis have been reported with this type of medicines. Systemic undesirable reactions following the topical use of ibuprofen are unlikely as the plasma levels of ibuprofen detected following the application of DICLOREUM UNIDIE are much lower than those detectable with the systemic administration of ibuprofen-based drugs. However, following applications for long periods of time, beyond the recommended term and failure to comply with contraindications and warnings, it is not possible to exclude the appearance of systemic side effects, especially at a gastrointestinal level (see paragraphs 4.4 and 5.2). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730207867207,"sku":"037184013","price":18.97,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-dicloreum-unidie-136-mg-5-cerotti-medicati-farmacia-dottor-tili-1213791086.jpg?v=1767140489"},{"product_id":"vegetallumina-antidolo-re-10-50-g-gel","title":"Vegetalumina Antipain 10% 50 g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of bruises, sprains, myalgia, muscle strains, stiff neck.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Due to the possibility of cross-sensitization, the medicine must not be administered to patients in whom acetylsalicylic acid or other non-steroidal anti-inflammatory drugs have caused asthma, rhinitis, urticaria or other allergic manifestations. - Pregnancy. - Breastfeeding. - Children and adolescents under 14 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt is advisable to avoid applying VEGETALLUMINA Antidolore to open wounds or skin lesions. The use of VEGETALLUMINA Antidolore, like any drug that inhibits the synthesis of prostaglandins and cyclooxygenase, is not recommended in women who intend to become pregnant. The administration of VEGETALLUMINA Antidolore must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use of VEGETALLUMINA Antidolore, especially if prolonged, can give rise to local sensitization phenomena: at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity, interrupt treatment and adopt adequate therapeutic measures. To avoid more serious hypersensitivity or photosensitivity phenomena, the patient must not expose himself to direct sunlight, including the solarium, during treatment and in the following two weeks. In case of allergic reactions or more serious adverse reactions (skin reactions, some of which are fatal, such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis) it is necessary to immediately suspend therapy at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity (see section 4.8). Patients appear to be at higher risk in the early stages of therapy: the onset of skin reactions occurs in most cases within the first month of treatment. \u003cb\u003eDo not use VEGETALLUMINA Antidolore together with another NSAID or, in any case, do not use more than one NSAID at a time.\u003c\/b\u003e \u003cb\u003eImportant information about some excipients of VEGETALLUMINA Antidolore\u003c\/b\u003e Anti-pain Vegetallumina contains lavender essence which in turn contains citral, citronellol, coumarin, eugenol, Evernia furfuracea extract, Evernia prunastri extract, geraniol, limonene, linalool. Citral, citronellol, coumarin, eugenol, geraniol, limonene, linalool can cause allergic reactions. This medicinal product contains sodium methyl parahydroxybenzoate and sodium ethyl parahydroxybenzoate. Sodium methylhydroxy benzoate and sodium ethylhydroxy benzoate can cause allergic reactions (even delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe paucity of data and the uncertainties relating to their application to the clinical situation do not allow definitive conclusions to be drawn on possible interactions with other drugs for the continuous use of ibuprofen; no clinically relevant interactions have been found with the occasional use of ibuprofen. Bear in mind, in any case, that Ibuprofen can increase the effects of anticoagulants such as warfarin. \u003ci\u003ePediatric population\u003c\/i\u003e There is no data available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Skin reactions with erythema, itching, irritation, sensation of heat or burning and contact dermatitis have been reported with some non-steroidal anti-inflammatory drugs derived from propionic acid for local or transdermal use. Some cases of bullous eruptions of varying severity have also been reported, including Stevens Johnson syndrome, toxic epidermal necrolysis (very rarely) and photosensitivity reactions (frequency not known). \u003ci\u003ePediatric population\u003c\/i\u003e There is no data available. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system of the Italian Medicines Agency at: http:\/\/www.aifa.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e","brand":"Pietrasanta Pharma","offers":[{"title":"Default Title","offer_id":51730211176775,"sku":"041734017","price":9.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/pietrasanta-pharma-spa-vegetallumina-antidolo-re-10-50-g-gel-farmacia-dottor-tili-1213791034.jpg?v=1767164627"},{"product_id":"flectorartro-1-100-g-gel-in-contenitore-pressurizzato","title":"FlectorArtro 1% 100g gel in pressurized container","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic local relief of pain and inflammatory states caused by post-traumatic injuries, such as contusions, sprains and tendonitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine is contraindicated in the following cases: – Hypersensitivity to diclofenac, acetylsalicylic acid (aspirin) or other NSAIDs. – Hypersensitivity to any other component of the gel. – Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by the action of acetylsalicylic acid or non-steroidal anti-inflammatory drugs (NSAIDs). – Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. – Starting from the third trimester of pregnancy (see section 4.6). – Use in children and adolescents under 15 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by administering the lowest effective dose for the shortest duration necessary to control symptoms, without exceeding a maximum period of two weeks (See sections 4.2 and 4.8). The possibility of systemic adverse events produced by the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see product information relating to other systemic forms of diclofenac). Although the onset of effects at a systemic level is very rare, caution should be used when using the gel in patients with renal, cardiac or hepatic impairment, previous history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis. Nonsteroidal anti-inflammatory drugs should be used with particular caution in elderly patients, who are more predisposed to the onset of adverse events. Diclofenac for topical use should only be applied to intact, non-broken skin, not to lesions or open wounds. It must not come into contact with the eyes or mucous membranes and must not be ingested. Stop treatment if you develop a skin rash after applying the product. Diclofenac for topical use can be used with non-occlusive dressings, but should not be used with non-breathable occlusive dressings. Patients should be informed about the contraindication to direct sun exposure and artificial UV rays in order to reduce the risk of photosensitivity. The use of gloves is recommended for the physiotherapist. Diclofenac for topical use in gel contains propylene glycol which may cause mild localized skin irritation in some subjects. The presence of methyl benzoate causes irritation of the skin, eyes and mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac from topical application of the gel is very low, interactions with other medicinal products are unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are classified by frequency, the highest frequency first, with the following convention: very common: (\u003e1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioneurotic edema\u003c\/p\u003e\n\u003cp\u003eNot known | Anaphylactic type reaction\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Pustular eruption\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (allergic and contact), pruritus\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac for topical application is very low compared to the levels of the active ingredient present in the plasma after taking oral diclofenac. The probability of systemic side effects (such as gastrointestinal (e.g. bleeding), hepatic or renal disorders) is therefore very low after topical application compared to the frequency of side effects associated with taking oral diclofenac. However, the use of diclofenac on a large skin area may lead to the onset of systemic side effects. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":51730211242311,"sku":"041472046","price":14.79,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-flectorartro-1-100-g-gel-in-contenitore-pressurizzato-farmacia-dottor-tili-1213791032.jpg?v=1767164589"},{"product_id":"dicloreum-actigel-1-100-g-gel","title":"Dicloreum Actigel 1% 100 g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor the local treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIndividual hypersensitivity confirmed towards the components of the product. Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs), as well as isopropanol. Contraindicated in the third trimester of pregnancy (see section 4.6 \u003ci\u003eFertility, pregnancy and breastfeeding\u003c\/i\u003e). \u003ci\u003e \u003cu\u003eChildren and adolescents\u003c\/u\u003e \u003c\/i\u003e Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac). DICLOREUM ACTIGEL must not be applied to skin wounds or open lesions, but only to intact skin. Avoid the preparation coming into contact with the eyes and mucous membranes. The gel should not be swallowed. In elderly patients and\/or with gastric problems, the concomitant use of systemic anti-inflammatory drugs is not recommended. Asthmatic patients, with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to antirheumatic treatment carried out with NSAIDs more often than other patients. The use, especially if prolonged, of other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Discontinue treatment if skin rash develops after application of the product. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eKeep the medicine out of the sight and reach of children.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough bioavailability studies show that an interaction with other drugs is unlikely, in high-dose and prolonged treatments the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins should be kept in mind.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c1\/10); uncommon (≥ 1\/1,000, \u003c1\/100); rare (≥ 1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Rash with pustules\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reaction.\u003c\/p\u003e\n\u003cp\u003eThe use of the product in combination with other drugs containing diclofenac can give rise to phenomena of hypersensitivity to light, skin rash with the formation of vesicles, eczema, erythema and skin reactions with severe evolution (Stevens-Johnson syndrome, Lyell syndrome).\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730211832135,"sku":"035450028","price":14.42,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-dicloreum-actigel-1-100-g-gel-farmacia-dottor-tili-1213791015.jpg?v=1767164968"},{"product_id":"voltaren-emulgel-1-gel-60-g","title":"Voltaren Emulgel 1% Gel 60 g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Patients in whom asthma, angioedema, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Third trimester of pregnancy. \u003cu\u003eChildren and adolescents\u003c\/u\u003e: Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac\u003ci\u003e).\u003c\/i\u003e Topical diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g and 4 mg of benzyl benzoate per dose (4 g) equivalent to 1 mg\/g which may cause skin irritation. \u003cb\u003e \u003ci\u003eVoltaren Emulgel 1% gel contains Cream 45 perfume, an aroma which in turn contains benzyl alcohol, citral, citronellol, coumarin, d-limonene, eugenol, farinasol, geraniol, linalool which may cause allergic reactions.\u003c\/i\u003e \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: very common (≥1\/10), common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Rash with pustules.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reaction, allergic reactions.\u003c\/p\u003e\n\u003cp\u003eNot known | Burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":53137878024519,"sku":"034548178","price":7.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/novartis-farma-spa-Voltaren_Emulgel_1_Gel_60_g-farmacia-dottor-tili-1216497345.jpg?v=1774447396"},{"product_id":"muscoril-dolore-gel-20-mg-g-dolori-muscolari-100-g","title":"Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g","description":"\u003cp\u003e\u003cstrong\u003eMuscoril Pain Gel 20 mg\/g Muscle Pain 100 g\u003c\/strong\u003e is a medicine for cutaneous use based on \u003cstrong\u003ediclofenac\u003c\/strong\u003e, an active ingredient belonging to the class of \u003cstrong\u003enon-steroidal anti-inflammatory drugs (NSAIDs)\u003c\/strong\u003e, known for its properties \u003cstrong\u003eanti-inflammatory and analgesic\u003c\/strong\u003e. The gel formulation is designed to be applied directly to the painful area, promoting a targeted action useful for reducing pain, inflammation and swelling in muscle and joint tissues.\u003c\/p\u003e\n\u003cp\u003eThis medicine is indicated for \u003cstrong\u003elocal symptomatic treatment of muscle pain\u003c\/strong\u003e caused by trauma or overload, such as \u003cstrong\u003emuscle strains, sprains and bruises\u003c\/strong\u003e, frequent situations during sporting activity or following small daily accidents. The action of diclofenac helps to counteract local inflammatory processes, helping to improve the comfort and mobility of the affected area.\u003c\/p\u003e\n\u003cp\u003eThe gel consistency allows for a \u003cstrong\u003eeasy application on the skin\u003c\/strong\u003e and rapid absorption without excessive grease, making the product practical to use in the daily routine. Muscoril Pain Gel is indicated for \u003cstrong\u003eadults and adolescents aged 14 and over\u003c\/strong\u003e and represents a useful solution for the targeted treatment of \u003cstrong\u003elocalized muscle pain\u003c\/strong\u003e and discomfort associated with minor trauma.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g used? What is it for?\u003c\/h3\u003e\u003cp\u003eMUSCORIL PAIN contains the active ingredient diclofenac which belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).\u003c\/p\u003e\u003cp\u003eMUSCORIL PAIN is indicated:\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eFor adults and adolescents aged 14 and over\u003c\/strong\u003e\u003cbr\u003eFor the local symptomatic treatment of pain associated with acute muscle strains, sprains or bruises following impact trauma, such as sports injuries and accidents.\u003c\/p\u003e\u003cp\u003eFor adolescents aged 14 years and older the medicine is indicated for short-term treatment.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g?\u003c\/h3\u003e\u003cp\u003e100 g of gel contain: active ingredient diclofenac 20 mg\/g.\u003c\/p\u003e\u003cp\u003eFor the complete list of excipients, see the information leaflet in the package.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g?\u003c\/h3\u003e\u003cp\u003eApply the gel to the affected area, massaging lightly until completely absorbed.\u003c\/p\u003e\u003cp\u003eAfter application, wash your hands, unless they are the site of the treatment.\u003c\/p\u003e\u003cp\u003eThe medicine is indicated for adults and adolescents aged 14 years and older.\u003c\/p\u003e\u003cp\u003eIn adolescents the medicine is indicated for short-term treatment.\u003c\/p\u003e\u003cp\u003eConsult your doctor if symptoms worsen or do not improve within 3 to 5 days.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eDo not use MUSCORIL DOLORE:\u003c\/p\u003e\u003cp\u003e- if you are allergic to diclofenac or any of the other ingredients of this medicine;\u003cbr\u003e- if you have developed attacks of asthma, hives, runny nose (acute rhinitis) after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs);\u003cbr\u003e- on open wounds, inflammation or skin infections, on eczema or on mucous membranes;\u003cbr\u003e- if you are in the last 3 months of pregnancy;\u003cbr\u003e- in children and adolescents under 14 years of age.\u003c\/p\u003e\u003cp\u003eLike all medicines, this medicine can cause side effects, although not everybody gets them.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eRare side effects\u003c\/strong\u003e (may affect up to 1 in 1,000 people)\u003c\/p\u003e\u003cp\u003e• Inflammation of the skin with blisters (bullous dermatitis).\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eVery rare side effects\u003c\/strong\u003e (may affect up to 1 in 10,000 people)\u003c\/p\u003e\u003cp\u003e• Asthma;\u003cbr\u003e• Swelling of the face, lips, tongue or throat (angioedema).\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eMunicipalities\u003c\/strong\u003e (may affect up to 1 in 10 people)\u003c\/p\u003e\u003cp\u003e• Rash, redness of the skin (erythema), dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eUncommon\u003c\/strong\u003e (may affect up to 1 in 100 people)\u003c\/p\u003e\u003cp\u003e• Scaling, dehydration of the skin, edema.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eVery rare\u003c\/strong\u003e (may affect up to 1 in 10,000 people)\u003c\/p\u003e\u003cp\u003e• Skin rash with pustules;\u003cbr\u003e• Gastrointestinal disorders;\u003cbr\u003e• Hypersensitivity reactions, including urticaria;\u003cbr\u003e• Photosensitivity reactions.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eFrequency not known\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e• Burning sensation at the application site.\u003c\/p\u003e\u003cp\u003eWhen MUSCORIL DOLORE is applied to a large area of ​​skin and for a prolonged period, the possibility of systemic side effects similar to those that may appear after the systemic administration of medicines containing diclofenac cannot be excluded.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g?\u003c\/h3\u003e\u003cp\u003eTalk to your doctor or pharmacist before using MUSCORIL DOLORE.\u003c\/p\u003e\u003cp\u003eIf you suffer from asthma, allergic rhinitis, swelling of the nasal mucosa (nasal polyps) or chronic obstructive pulmonary disease, chronic respiratory tract infections (associated in particular with symptoms similar to allergic rhinitis), you are more exposed to asthma attacks, local swelling of the skin or mucous membranes (Quincke's edema) and urticaria.\u003c\/p\u003e\u003cp\u003eWhen MUSCORIL DOLORE is applied to a large area of ​​skin and for a prolonged period, the possibility of systemic side effects cannot be excluded.\u003c\/p\u003e\u003cp\u003eApply MUSCORIL DOLORE only on intact, healthy and wound-free skin. Avoid contact with eyes and oral mucous membranes. The gel should not be swallowed.\u003c\/p\u003e\u003cp\u003eAfter applying the gel to the skin, you can use a breathable (non-occlusive) bandage, but you must first let the gel dry on the skin for a few minutes.\u003c\/p\u003e\u003cp\u003eDo not use it with occlusive bandages that do not let air pass.\u003c\/p\u003e\u003cp\u003eConsult your doctor if symptoms worsen or do not improve within 3 to 5 days.\u003c\/p\u003e\u003cp\u003eThe use of MUSCORIL DOLORE should be stopped if you develop a skin rash.\u003c\/p\u003e\u003cp\u003eAvoid exposure to sunlight, including sunlamps, while using this medicine.\u003c\/p\u003e\u003cp\u003eNecessary precautions should be taken to prevent children from touching the area to which the gel is applied.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g stored?\u003c\/h3\u003e\u003cp\u003eStore the medicine according to the instructions on the package.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Muscoril Pain Gel 20 mg\/g Muscle Pain 100 g?\u003c\/h3\u003e\u003cp\u003e100 g\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Doc Generici","offers":[{"title":"Default Title","offer_id":53463748018503,"sku":"051378026","price":17.58,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/doc-generici-srl-muscoril-dolore-gel-20-mg-g-dolori-muscolari-100-g-farmacia-dottor-tili-1226760408.webp?v=1774447393"},{"product_id":"muscoril-dolore-gel-20-mg-g-dolori-muscolari-60-g","title":"Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g","description":"\u003cp\u003e\u003cstrong\u003eMuscoril Pain Gel 20 mg\/g Muscle Pain 60 g\u003c\/strong\u003e is a medicine for cutaneous use based on diclofenac, an active ingredient belonging to the class of non-steroidal anti-inflammatory drugs (NSAIDs), known for its anti-inflammatory and analgesic properties. The gel formulation is designed to be applied directly to the painful area, promoting a targeted action useful for reducing pain, inflammation and swelling in muscle and joint tissues.\u003c\/p\u003e\n\u003cp\u003eThis medicine is indicated for the local symptomatic treatment of muscle pain caused by trauma or overload, such as muscle strains, sprains and bruises, frequent situations during sporting activity or following small daily accidents. The action of diclofenac helps to counteract local inflammatory processes, helping to improve the comfort and mobility of the affected area.\u003c\/p\u003e\n\u003cp\u003eThe gel consistency allows for easy application on the skin and rapid absorption without being excessively greasy, making the product practical to use in your daily routine. Muscoril Pain Gel is indicated for adults and adolescents aged 14 and over and represents a useful solution for the targeted treatment of localized muscle pain and discomfort associated with minor trauma.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g used? What is it for?\u003c\/h3\u003e\u003cp\u003eMUSCORIL PAIN contains the active ingredient diclofenac which belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).\u003c\/p\u003e\u003cp\u003eMUSCORIL PAIN is indicated:\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eFor adults and adolescents aged 14 and over\u003c\/strong\u003e\u003cbr\u003eFor the local symptomatic treatment of pain associated with acute muscle strains, sprains or bruises following impact trauma, such as sports injuries and accidents.\u003c\/p\u003e\u003cp\u003eFor adolescents aged 14 years and older the medicine is indicated for short-term treatment.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g?\u003c\/h3\u003e\u003cp\u003e100 g of gel contain: active ingredient diclofenac 20 mg\/g.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eFor the complete list of excipients, see the information leaflet in the package.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g?\u003c\/h3\u003e\u003cp\u003eApply the gel to the affected area, massaging lightly until completely absorbed.\u003c\/p\u003e\u003cp\u003eAfter application, wash your hands, unless they are the site of the treatment.\u003c\/p\u003e\u003cp\u003eThe medicine is indicated for adults and adolescents aged 14 years and older.\u003c\/p\u003e\u003cp\u003eIn adolescents the medicine is indicated for short-term treatment.\u003c\/p\u003e\u003cp\u003eConsult your doctor if symptoms worsen or do not improve within 3 to 5 days.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eDo not use MUSCORIL DOLORE:\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eif you are allergic to diclofenac or any of the other ingredients of this medicine;\u003c\/li\u003e\n\u003cli\u003eif you have developed attacks of asthma, hives, runny nose (acute rhinitis) after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs);\u003c\/li\u003e\n\u003cli\u003eon open wounds, inflammation or skin infections, on eczema or on mucous membranes;\u003c\/li\u003e\n\u003cli\u003eif you are in the last 3 months of pregnancy;\u003c\/li\u003e\n\u003cli\u003ein children and adolescents under 14 years.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eLike all medicines, this medicine can cause side effects, although not everybody gets them.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eRare side effects\u003c\/strong\u003e (may affect up to 1 in 1,000 people)\u003c\/p\u003e\u003cul\u003e\u003cli\u003eInflammation of the skin with blisters (bullous dermatitis).\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eVery rare side effects\u003c\/strong\u003e (may affect up to 1 in 10,000 people)\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eAsthma;\u003c\/li\u003e\n\u003cli\u003eSwelling of the face, lips, tongue or throat (angioedema).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eMunicipalities\u003c\/strong\u003e (may affect up to 1 in 10 people)\u003c\/p\u003e\u003cul\u003e\u003cli\u003eRash, redness of the skin (erythema), dermatitis (including contact dermatitis), pruritus.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eUncommon\u003c\/strong\u003e (may affect up to 1 in 100 people)\u003c\/p\u003e\u003cul\u003e\u003cli\u003eScaling, skin dehydration, edema.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eVery rare\u003c\/strong\u003e (may affect up to 1 in 10,000 people)\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSkin rash with pustules;\u003c\/li\u003e\n\u003cli\u003eGastrointestinal disorders;\u003c\/li\u003e\n\u003cli\u003eHypersensitivity reactions, including urticaria;\u003c\/li\u003e\n\u003cli\u003ePhotosensitivity reactions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eFrequency not known\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\u003cli\u003eBurning sensation at the application site.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eWhen MUSCORIL DOLORE is applied to a large area of ​​skin and for a prolonged period, the possibility of systemic side effects similar to those that may appear after the systemic administration of medicines containing diclofenac cannot be excluded.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g?\u003c\/h3\u003e\u003cp\u003eTalk to your doctor or pharmacist before using MUSCORIL DOLORE.\u003c\/p\u003e\u003cp\u003eIf you suffer from asthma, allergic rhinitis, swelling of the nasal mucosa (nasal polyps) or chronic obstructive pulmonary disease, chronic respiratory tract infections (associated in particular with symptoms similar to allergic rhinitis), you are more exposed to asthma attacks, local swelling of the skin or mucous membranes (Quincke's edema) and urticaria.\u003c\/p\u003e\u003cp\u003eWhen MUSCORIL DOLORE is applied to a large area of ​​skin and for a prolonged period, the possibility of systemic side effects cannot be excluded.\u003c\/p\u003e\u003cp\u003eApply MUSCORIL DOLORE only on intact, healthy and wound-free skin. Avoid contact with eyes and oral mucous membranes. The gel should not be swallowed.\u003c\/p\u003e\u003cp\u003eAfter applying the gel to the skin, you can use a breathable (non-occlusive) bandage, but you must first let the gel dry on the skin for a few minutes.\u003c\/p\u003e\u003cp\u003eDo not use it with occlusive bandages that do not let air pass.\u003c\/p\u003e\u003cp\u003eConsult your doctor if symptoms worsen or do not improve within 3 to 5 days.\u003c\/p\u003e\u003cp\u003eThe use of MUSCORIL DOLORE should be stopped if you develop a skin rash.\u003c\/p\u003e\u003cp\u003eAvoid exposure to sunlight, including sunlamps, while using this medicine.\u003c\/p\u003e\u003cp\u003eNecessary precautions should be taken to prevent children from touching the area to which the gel is applied.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g stored?\u003c\/h3\u003e\u003cp\u003eStore the medicine according to the instructions on the package.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Muscoril Pain Gel 20 mg\/g Muscle Pain 60 g?\u003c\/h3\u003e\u003cp\u003e60 g\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Doc Generici","offers":[{"title":"Default Title","offer_id":53463748280647,"sku":"051378014","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/doc-generici-srl-muscoril-dolore-gel-20-mg-g-dolori-muscolari-60-g-farmacia-dottor-tili-1226785823.jpg?v=1773164828"},{"product_id":"muscoridol-5-cerotti-medicati-dolore-muscolare-180-mg","title":"Muscoridol 5 Medicated Patches for Muscle Pain 180 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal symptomatic treatment of rheumatic or traumatic pain and inflammation of joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product is contraindicated in the following cases: - Hypersensitivity to diclofenac, acetylsalicylic acid, other analgesics or other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients listed in section 6.1. - Patients who have had asthma attacks, urticaria or acute rhinitis triggered by acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. - Third trimester of pregnancy (see section 4.6). - Patients with active peptic ulcer. - Children and adolescents under the age of 16.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- The medicated plaster must only be applied to intact and healthy skin and must not be applied to damaged skin or open wounds and must not be applied when bathing or showering. - The medicated plaster must not come into contact with or be applied to the mucous membranes or eyes. - Do not use with an occlusive dressing that does not let air pass. - Treatment must be stopped immediately if a rash develops after applying the medicated plaster. - Do not administer simultaneously, topically or systemically, another medicinal product based on diclofenac or other NSAIDs. - The possibility of systemic adverse events produced by the application of topical diclofenac cannot be excluded if the preparation is used on a large skin surface and for a prolonged period (see product information relating to other systemic forms of diclofenac). Although systemic effects may be minimal, the patch should be used with caution in patients with impaired renal, cardiac or hepatic function, a history of peptic ulcer, intestinal inflammation or haemorrhagic diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients, as they are more susceptible to the onset of side effects. - Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removing the medicated plaster in order to reduce the risk of photosensitivity. - The medicated plaster should be used with caution in patients with asthma, chronic bronchial obstructive disease, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) who may react with asthma attacks, local inflammation of the skin or mucous membranes (Quincke's edema), urticaria or acute rhinitis after treatment with acetylsalicylic acid or other non-steroidal anti-inflammatory agents more often than other patients (see section 4.3). - In order to minimize the occurrence of side effects, it is recommended to use the lowest effective dose for the shortest duration necessary to control symptoms, without exceeding the approved maximum of 14 days (see sections 4.2 and 4.8). - The use, especially if prolonged, of this as well as other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. - Although systemic absorption is minimal, however the use of the medicated plaster, as of any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant (see section 4.6). - The administration of the diclofenac-based medicated plaster must be suspended in women who have fertility problems or who are undergoing fertility investigations (see section 4.6). This medicine contains \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e e \u003cb\u003epropyl parahydroxybenzoate\u003c\/b\u003e. They can cause allergic reactions (even delayed); This medicine contains 420 mg of \u003cb\u003epropylene glycol\u003c\/b\u003e per patch.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible. Clinical investigations carried out with the diclofenac-based medicated plaster, used in conjunction with other steroidal and non-steroidal anti-inflammatory drugs (salazopyrin, hydroxyquinoline, etc.), have not highlighted any interaction phenomena. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs (see section 4.8) is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions are listed by frequency, the most frequent first, using the following convention: very common (\u003e1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Pustular rash\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioedema, anaphylactic reaction\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus\u003c\/p\u003e\n\u003cp\u003eUncommon | Petechiae\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis (e.g. bullous erythema), dry skin\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eNot known | Burning sensation at the application site\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Reactions at the site of administration\u003c\/p\u003e\n\u003cp\u003eUncommon | Feeling hot\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac is very low compared to the plasma levels measured after oral intake of diclofenac and the probability of systemic side effects (such as gastric, hepatic and renal disorders) is very low compared to the frequency of side effects associated with oral use of diclofenac. However, if Zaranny is used on large skin surfaces and for long periods of time, the appearance of systemic side effects is possible, especially at the gastrointestinal level due to the amount of active ingredient that is absorbed. The use of the product in combination with other drugs containing diclofenac must be avoided as it can give rise to phenomena of hypersensitivity to light, skin rash with vesicle formation, eczema, erythema and, in rare cases, severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome) (see paragraphs 4.4 and 4.5). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Doc Generici","offers":[{"title":"Default Title","offer_id":53495604248903,"sku":"045951011","price":15.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/doc-generici-srl-muscoridol-5-cerotti-medicati-dolore-muscolare-180-mg-farmacia-dottor-tili-1226919704.webp?v=1774447392"},{"product_id":"muscoridol-10-cerotti-medicati-dolore-muscolare-180-mg","title":"Muscoridol 10 Medicated Patches for Muscle Pain 180 mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal symptomatic treatment of rheumatic or traumatic pain and inflammation of joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product is contraindicated in the following cases: - Hypersensitivity to diclofenac, acetylsalicylic acid, other analgesics or other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients listed in section 6.1. - Patients who have had asthma attacks, urticaria or acute rhinitis triggered by acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. - Third trimester of pregnancy (see section 4.6). - Patients with active peptic ulcer. - Children and adolescents under the age of 16.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- The medicated plaster must only be applied to intact and healthy skin and must not be applied to damaged skin or open wounds and must not be applied when bathing or showering. - The medicated plaster must not come into contact with or be applied to the mucous membranes or eyes. - Do not use with an occlusive dressing that does not let air pass. - Treatment must be stopped immediately if a rash develops after applying the medicated plaster. - Do not administer simultaneously, topically or systemically, another medicinal product based on diclofenac or other NSAIDs. - The possibility of systemic adverse events produced by the application of topical diclofenac cannot be excluded if the preparation is used on a large skin surface and for a prolonged period (see product information relating to other systemic forms of diclofenac). Although systemic effects may be minimal, the patch should be used with caution in patients with impaired renal, cardiac or hepatic function, a history of peptic ulcer, intestinal inflammation or haemorrhagic diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients, as they are more susceptible to the onset of side effects. - Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removing the medicated plaster in order to reduce the risk of photosensitivity. - The medicated plaster should be used with caution in patients with asthma, chronic bronchial obstructive disease, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) who may react with asthma attacks, local inflammation of the skin or mucous membranes (Quincke's edema), urticaria or acute rhinitis after treatment with acetylsalicylic acid or other non-steroidal anti-inflammatory agents more often than other patients (see section 4.3). - In order to minimize the occurrence of side effects, it is recommended to use the lowest effective dose for the shortest duration necessary to control symptoms, without exceeding the approved maximum of 14 days (see sections 4.2 and 4.8). - The use, especially if prolonged, of this as well as other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. - Although systemic absorption is minimal, however the use of the medicated plaster, as of any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant (see section 4.6). - The administration of the diclofenac-based medicated plaster must be suspended in women who have fertility problems or who are undergoing fertility investigations (see section 4.6). This medicine contains \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e e \u003cb\u003epropyl parahydroxybenzoate\u003c\/b\u003e. They can cause allergic reactions (even delayed); This medicine contains 420 mg of \u003cb\u003epropylene glycol\u003c\/b\u003e per patch.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible. Clinical investigations carried out with the diclofenac-based medicated plaster, used in conjunction with other steroidal and non-steroidal anti-inflammatory drugs (salazopyrin, hydroxyquinoline, etc.), have not highlighted any interaction phenomena. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs (see section 4.8) is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions are listed by frequency, the most frequent first, using the following convention: very common (\u003e1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Pustular rash\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Hypersensitivity (including urticaria), angioedema, anaphylactic reaction\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare | Asthma\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus\u003c\/p\u003e\n\u003cp\u003eUncommon | Petechiae\u003c\/p\u003e\n\u003cp\u003eRare | Bullous dermatitis (e.g. bullous erythema), dry skin\u003c\/p\u003e\n\u003cp\u003eVery rare | Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eNot known | Burning sensation at the application site\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eMunicipality | Reactions at the site of administration\u003c\/p\u003e\n\u003cp\u003eUncommon | Feeling hot\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac is very low compared to the plasma levels measured after oral intake of diclofenac and the probability of systemic side effects (such as gastric, hepatic and renal disorders) is very low compared to the frequency of side effects associated with oral use of diclofenac. However, if Zaranny is used on large skin surfaces and for long periods of time, the appearance of systemic side effects is possible, especially at the gastrointestinal level due to the amount of active ingredient that is absorbed. The use of the product in combination with other drugs containing diclofenac must be avoided as it can give rise to phenomena of hypersensitivity to light, skin rash with vesicle formation, eczema, erythema and, in rare cases, severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome) (see paragraphs 4.4 and 4.5). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Doc Generici","offers":[{"title":"Default Title","offer_id":53495796924743,"sku":"045951023","price":22.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/doc-generici-srl-muscoridol-10-cerotti-medicati-dolore-muscolare-180-mg-farmacia-dottor-tili-1226919702.jpg?v=1773236830"},{"product_id":"14-mg-cerotto-medicato-10-cerotti-in-bustina-carta-pe-al-eaa","title":"Flector Unidie 14 mg 10 piroxicam medicated plasters","description":"\u003cp\u003eFlector Unidie is \u003cstrong\u003epiroxicam 14 mg\u003c\/strong\u003e in a medicated plaster. Piroxicam is a \u003cstrong\u003enon-steroidal anti-inflammatory\u003c\/strong\u003e, and the patch form serves to take it where it is needed without letting it all pass through the stomach: the levels in the blood that are reached this way are much lower than those of the tablet.\u003c\/p\u003e\u003cp\u003eThe name says the most useful thing to know. \u003cstrong\u003eUnidie\u003c\/strong\u003e it means \u003cstrong\u003eone patch every twenty-four hours\u003c\/strong\u003e, only one at a time, and never two on the same day. The cycle must not exceed \u003cstrong\u003eeight days\u003c\/strong\u003e. It applies only to the \u003cstrong\u003eintact skin\u003c\/strong\u003e, after having washed and dried the area well: rub a corner of the patch between your fingers to detach the protective film and place the adhesive part on the skin.\u003c\/p\u003e\u003cp\u003eOn the elbow and knee, which bend a lot, the RCP suggests a \u003cstrong\u003eretention bandage\u003c\/strong\u003e to be placed with the joint flexed, so the patch remains in place even when the joint opens.\u003c\/p\u003e\u003cp\u003eThe things that remain are that, being an NSAID, piroxicam also comes with it through the skin. The blood level is low but \u003cstrong\u003eIt varies a lot from person to person\u003c\/strong\u003e, therefore general effects cannot be excluded, especially on the stomach. And repeated use of skin products can cause \u003cstrong\u003eawareness\u003c\/strong\u003e: if redness, itching or burning appear at the application site, stop. Even better \u003cstrong\u003eavoid direct sun\u003c\/strong\u003e on the treated area, to avoid the risk of photosensitisation. This is the pack from \u003cstrong\u003e10 plasters\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Flector Unidie 14 mg 10 piroxicam medicated plasters used? What is it for?\u003c\/h3\u003e\u003cp\u003eFlector Unidie is indicated for the treatment of painful and inflammatory states of a rheumatic and traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eComposition\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eA medicated plaster contains: • active ingredient: piroxicam 14 mg. \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eExcipients\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eAcrylic copolymer, Eudragit E 100; non-woven fabric, silicone polyester.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow is Flector Unidie 14 mg 10 piroxicam medicated plasters taken?\u003c\/h3\u003e\u003cp\u003eDosage It is recommended to use only one medicated plaster at a time and replace it every 24 hours for a period of no more than 8 days. Do not apply two patches on the same day. Flector Unidie is to be used exclusively on intact skin. Method of administration For cutaneous use only. After having carefully washed and dried the painful area, rub one of the corners of Flector Unidie between your fingers to remove the protective film and apply the adhesive part directly to the skin. In the event that Flector Unidie must be applied to joints with greater mobility, such as the elbow or knee, it is advisable to use a retention bandage to be applied to the flexed joint, in order to keep the patch in place. Do not exceed the recommended doses. Avoid contact with eyes and mucous membranes.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Flector Unidie 14 mg 10 piroxicam medicated plasters not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eContraindications\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eFlector Unidie is contraindicated in the following cases: • hypersensitivity to the active ingredient (piroxicam) or to any of the excipients (see the section \"What is the composition of Flector Unidie 14 mg 10 piroxicam medicated plasters?\"); • patients in whom substances with a similar mechanism of action (NSAIDs) have caused hypersensitivity reactions ((see the section \"What are the warnings of Flector Unidie 14 mg 10 piroxicam medicated plasters?\")); • patients with active peptic ulcer; • patients with bronchial asthma; • patients with a history of gastrointestinal bleeding due to NSAIDs; • patients on anticoagulant therapy; • pregnancy and breastfeeding ((see the section \"Can Flector Unidie 14 mg 10 piroxicam medicated plasters be used during pregnancy and breastfeeding?\")); • children under 12 years of age. Flector Unidie patch should not be used on open wounds or lesions, but only on intact skin.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSide effects\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThe use of the medicine can cause local irritative or allergic skin reactions such as erythema, itching, burning, contact dermatitis, numbness and tingling at the application site; cases of extensive and serious dermatological lesions such as urticaria, Quincke's edema, erythema multiforme have been reported with this type of medicine. Larger and more severe photosensitivity reactions and skin and mucosal reactions, including asthma attacks, are possible. Systemic adverse reactions following the topical use of piroxicam are unlikely; since the plasma levels obtained are lower than those measured after systemic administration but highly variable from individual to individual, it is not possible to exclude, especially in the case of prolonged therapies beyond the recommended term and non-observance of contraindications and warnings, the appearance of systemic side effects, especially at a gastrointestinal level ((see the section \"What are the warnings for Flector Unidie 14 mg 10 piroxicam medicated plasters?\")). The possible appearance of general side effects or at the point of application requires suspension of therapy. Cases of fixed drug eruption with unknown frequency (frequency cannot be estimated from the available data) have been reported with piroxicam ((see section \"What are the warnings for Flector Unidie 14 mg 10 piroxicam medicated plasters?\")). Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can change the effect of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003eThe use of piroxicam-based patches is unlikely to have interactions with other medicines. However, the possibility of competition between the absorbed piroxicam and other drugs with high binding to plasma proteins cannot be excluded. Do not use the medicine together with other drugs for oral or local use, containing piroxicam or other NSAIDs.\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Flector Unidie 14 mg 10 piroxicam medicated plasters be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003ePregnancy and breastfeeding Flector Unidie is contraindicated during pregnancy and breastfeeding and is not recommended in women intending to become pregnant. Fertility Administration should be suspended in women with fertility problems or who are undergoing fertility investigations.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings and precautions\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThe serum levels achieved with Flector Unidie were significantly lower than those obtained through oral administration but with strong individual variability, therefore the onset of systemic side effects, especially at the gastrointestinal level, cannot be ruled out. Analgesics, antipyretics, non-steroidal anti-inflammatory drugs, including piroxicam, can cause hypersensitivity reactions, potentially serious even in subjects not previously exposed to this type of drugs. These include asthma attacks, skin rashes, allergic rhinitis and anaphylactic-type reactions. Flector Unidie should be used with caution in subjects with chronic obstructive bronchial diseases, allergic rhinitis or inflammation of the nasal mucosa (nasal polyps) in which asthmatic attacks or localized inflammatory reactions of the skin and mucosa (Quincke's edema) are more frequent. Use caution in patients with a history of peptic ulcer, in patients with a history of gastrointestinal bleeding not secondary to the administration of NSAIDs or with other bleeding disorders, in patients with Crohn's disease or ulcerative colitis, with severe hepatic or renal dysfunction or with heart failure. Prolonged or repeated use of products for skin use can give rise to sensitization phenomena. In the presence of hypersensitivity reactions it is necessary to interrupt therapy. Caution should be used when treating elderly patients who are generally more susceptible to adverse events. After a short therapy without results, consult your doctor. To avoid any phenomena of hypersensitivity or photosensitization, avoid exposure to direct sunlight. Skin reactions Cases of fixed drug eruption (FDE) have been reported with piroxicam. Piroxicam should not be reintroduced in patients with a history of piroxicam-related FDE. A potential cross-reaction with other oxicams may occur. Pediatric population Keep the medicine out of the sight and reach of children.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOverdose\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThere are no known cases of overdose. In case of overdose with evident clinical manifestations, immediately institute symptomatic therapy and apply the common emergency measures of the case.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDriving vehicles and using machinery\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eFlector Unidie does not interfere with the ability to drive vehicles and use machines.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Flector Unidie 14 mg 10 piroxicam medicated plasters stored?\u003c\/h3\u003e\u003cp\u003eNo particular storage conditions are necessary.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e10 medicated plasters of 14 mg\u003c\/strong\u003e, in paper, polyethylene, aluminum and EAA sachets.\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":54954303652167,"sku":"038354039","price":25.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-14-mg-cerotto-medicato-10-cerotti-in-bustina-carta-pe-al-eaa-farmacia-dottor-tili-1257817163.jpg?v=1790944642"}],"url":"https:\/\/www.dottortili.com\/en-eu\/collections\/topical-painkillers-drugs-and-patches.oembed?page=2","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}